Mercurial > repos > iuc > pysradb_search
view test-data/test_03.tabular @ 0:1005ffbccd86 draft
planemo upload for repository https://github.com/galaxyproject/tools-iuc/tree/master/tools/pysradb commit 95f13fef86ee81a617814a386cb371e94cf45577
| author | iuc |
|---|---|
| date | Fri, 11 Nov 2022 07:35:39 +0000 |
| parents | |
| children |
line wrap: on
line source
run_accession description DRR013000 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013001 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013002 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013003 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013004 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013005 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013006 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013007 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013008 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013009 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013010 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013011 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013012 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013013 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. DRR013014 Illumina Genome Analyzer IIx sequencing; Mutation profiles in inflamed gastric epithelium with Helicobacter pylori infection during the development of gastric cancer. ERR166302 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166303 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166304 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166305 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166306 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166307 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166308 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166309 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166310 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166311 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166312 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166313 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166314 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166315 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166316 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166317 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166318 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166319 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166320 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166321 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166322 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166323 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166324 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166325 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166326 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166327 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166328 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166329 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166330 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166331 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166332 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166333 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166334 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166335 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. ERR166336 Illumina Genome Analyzer II paired end sequencing; Whole exome sequencing suggests much of non BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.